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Background: This study aimed to characterize and differentiate the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) strategy 2011 cut points through the modified 
Medical Research Council dyspnea scale (mMRC) and chronic obstructive pulmonary disease 
(COPD) assessment test (CAT).
Methods: Analysis of COPD patient data from the 2012 Adelphi Respiratory Disease Specific 
Program was conducted in Europe and US. Matched data from physicians and patients included 
CAT and mMRC scores. Receiver operating characteristic curves and kappa analysis determined 
a cut point for CAT and mMRC alignment and thus defined patient movement (“movers”) within 
GOLD groups A–D, depending on the tool used. Logistic regression analysis, with a number of 
physician- and patient-reported covariates, characterized those movers.
Results: Comparing GOLD-defined high-symptom patients using mMRC and CAT cut points 
($2 and $10, respectively), there were 890 (53.65%) movers; 887 of them (99.66%) moved from 
less symptomatic GOLD groups A and C (using mMRC) to more symptomatic groups B and D 
(using CAT). For receiver operating characteristic (area under the curve: 0.82, P,0.001) and kappa 
(maximized: 0.45) recommended CAT cut points of $24 and $26, movers reduced to 429 and 403 
patients, respectively. Logistic regression analysis showed variables significantly associated with 
movers were related to impact on normal life, age, cough, and sleep (all P,0.05). Within movers, 
direction of movement was significantly associated with the same variables (all P,0.05).
Conclusion: Use of current mMRC or CAT cut points leads to inconsistencies for COPD 
assessment classification. It is recommended that cut points are aligned and both tools admin-
istered simultaneously for optimal patient care and to allow for closer management of movers. 
Our research may suggest an opportunity to investigate a combined score approach to patient 
management based on the worst result of mMRC and CAT. The reduced number of remaining 
movers may then identify patients who have greater impact of disease and may require a more 
personalized treatment plan.
Keywords: GOLD classification, mMRC, CAT, cut points, kappa analysis, receiver operating 
curves
Introduction
Chronic obstructive pulmonary disease (COPD) is a complex global disease, which 
requires a simple approach to management. In recognition of these complexities, the 
Global initiative for Chronic Obstructive Lung Disease (GOLD) group has provided 
recommendations for appropriate diagnosis and treatment of COPD. In 2011, the GOLD 
strategy1 moved away from a linear, one-dimensional classification of severity groups, 
defined solely by degree of airflow limitation (forced expiratory volume [FEV
1
]), to 
a two-dimensional assessment that takes into account exacerbation risk, measured by 
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exacerbation history and/or FEV
1
, and current symptoms, 
measured by either the modified Medical Research Council 
dyspnea scale (mMRC) or the COPD assessment test (CAT).2 
An updated GOLD report was released in January 2014 
based on further published scientific research since comple-
tion of the 2011 document but maintains the same treatment 
paradigm.3
This new classification creates four GOLD groups strati-
fied by exacerbation risk (low, high) and symptoms (low, 
high), with patient treatment recommendations dependent 
on group allocation: A: low risk, low symptoms; B: low 
risk, high symptoms; C: high risk, low symptoms; D: high 
risk, high symptoms.2 Exacerbation risk is defined by the 
greater level of either history of exacerbations in the previ-
ous year (0–1, low risk and 2+, high risk) or by spirometry-
determined airflow limitation (GOLD stages 1 and 2, low 
risk [FEV
1
$50% predicted] and stages 3 and 4, high risk 
[FEV
1
 ,50% predicted]). However, it should be noted that 
one or more hospitalizations for COPD exacerbations should 
be considered high risk.3 Current symptoms are measured 
by either the mMRC (0 or 1, low symptoms and 2+, high 
symptoms) or the CAT (,10, low symptoms and $10, 
high symptoms). GOLD recognizes that COPD is multi-
symptomatic and that mMRC measures breathlessness only. 
It therefore recommends that additional comprehensive 
symptom assessment is undertaken using questionnaires 
such as CAT.3
Real-world evidence has become an established method 
for examining treatment practices in primary and specialist 
care across a large number of disease areas, and demand 
continues for better evidence of the practical and real-world 
effects of treatments.4 It is complementary to data pro-
vided by randomized clinical trials and addresses gaps in 
current knowledge. In this research, the matched elements 
of physician-reported (exacerbations/FEV
1
) and patient-
reported (mMRC and CAT) variables provided a unique 
data source to enable the categorization of patients into the 
GOLD groups A to D.
This research sought to assess the implications of the 
revised GOLD strategy on the consulting population by 
understanding the degree of CAT and mMRC alignment 
given the cut points recommended by GOLD. Additionally, 
it aimed to characterize the patients who have a different 
GOLD classification depending on which instrument is 
used – the movers – and to determine a CAT cut point that 
would more closely align the two populations in order to 
provide a consistent approach to patient classification and 
treatment.
Materials and methods
study design and population
Data were from a retrospective analysis of the Adelphi 
Real World Respiratory Disease Specific Program (DSP) 
conducted from September to December 2012 in France, 
Germany, Spain, Italy, UK, and USA. These surveys are 
large, multinational, and cross-sectional and collect data 
from physicians and patients in real-world clinical settings 
thereby providing a holistic picture of a disease and its treat-
ment. They do not aim to demonstrate cause and effect and 
have no set hypothesis. The DSP is an established method for 
investigating multicenter treatment practices across a variety 
of disease areas. The full methodology has been published 
previously.5
Physicians were a geographically representative sample 
of primary care physicians and pulmonologists, who had 
qualified between 1977 and 2006, were actively involved in 
COPD management, and saw three or more COPD patients 
per physician in a typical week. Included subjects were the 
next six consulting patients of 40 years of age and older, 
with a history of smoking and with a confirmed diagnosis of 
COPD (COPD-only or with mixed COPD and asthma). For 
the purposes of this analysis, patients with a mixed asthma 
diagnosis were excluded. It was also deemed irrelevant 
for the purposes of this observational survey if physicians 
had applied, or were even aware of, GOLD criteria to their 
patients as GOLD categorization was performed retrospec-
tively on the dataset.
Data collection
Physicians completed a detailed patient record form, which 
included spirometry and exacerbation history, for the next six 
consecutive consulting COPD patients. The same patients were 
invited to fill out a voluntary, confidential, anonymized patient 
self-completion form. Unique numerical identifiers allowed 
matching of physician and patient recorded data. Questions 
related primarily to demographics, symptomology, quality 
of life, and disease burden, including EuroQol-5D6 and the 
Work Productivity and Activity Impairment Questionnaire.7 
Mandatory questions for inclusion in this analysis included 
completion of both the CAT8 and the mMRC.9,10
The mMRC is a patient-reported ordinal-rating scale 
measuring levels of dyspnea. Patients are asked which 
of five descriptions of breathlessness best describes their 
impairment, with a choice of 0, “only breathless with serious 
exercise”, to 4, “I am too breathless to leave the house”; high 
symptoms according to current GOLD recommendations 
equal $2.2 The CAT questionnaire measures the health status 
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of COPD patients. Eight statements describe best and worst 
case scenarios; patients decide where they fit on a scale of 
0–5 (best to worst) for each statement. The total score range 
is 0–40.8 High symptoms according to current GOLD recom-
mendation are $10.3
Symptom evaluation for a GOLD group (A–D) is defined 
by the results of one of these two questionnaires. For the 
purposes of this research, patients who were classified into 
different symptom groups, depending on the symptom ques-
tionnaire and cut point being used, were termed as movers.
The survey was performed according to the European 
Pharmaceutical Market Research Association guidelines11 
and in full accordance with the US Health Insurance 
Portability and Accountability Act 199612 and European 
equivalents.11,13 Each patient provided consent for deidenti-
fied and aggregated reporting of research findings as required 
by the guidelines. Data were deidentified prior to receipt by 
Adelphi.
statistical analysis
Receiver operating characteristic (ROC) curves analysis14 
was conducted to determine the optimal cut point of CAT 
to match the mMRC cut point of $2 recommended by the 
GOLD strategy. We employed nonparametric estimation 
of the ROC curve and selected the most appropriate CAT 
cut point by maximizing the Youden index,15–17 the sum 
of sensitivity and specificity. The area under the curve 
(AUC) was calculated using the Mann–Whitney–Wilcoxon 
test method; this can range between 0 and 1, representing 
expected performance. An AUC of 0.5 is equivalent to 
random guessing or the lack of a relationship, whereas an 
AUC of 1 is equivalent to the reference standard. Preliminary 
ROC curves analysis was also conducted to determine the 
optimal cut point of mMRC to match the CAT cut point 
of $10 recommended by the GOLD strategy. However, in 
all further analysis, mMRC was selected as the reference as 
it is more evenly split between low and high, and CAT has 
more granularity and potential cut points.
Furthermore, the kappa statistic18 was used as a measure 
of interrater agreement for qualitative (categorical) items, 
scaled to be 0 when the amount of agreement is what would be 
expected to be observed by chance and 1 when there is perfect 
agreement. We determined which CAT cut point maximized 
the agreement with the mMRC cut point of $2 in determin-
ing presence of current symptoms (low, high) per patient, as 
recommended by the GOLD group.
In order to investigate what characterized a mover and 
what characterized those who moved left/right, we ran 
separate logistic regression analyses, respectively, for the 
following dependent variables: 1) whether or not a patient 
has been categorized differently by CAT and mMRC cut 
points (movers versus non movers), and 2) whether the 
patient moved left or right (movers-left versus movers-
right) in the GOLD classification (for those categorized 
differently by CAT and mMRC cut points).
Standard errors were computed by adjusting for possible 
intragroup correlation within reporting physician. A list of 
covariates was as follows (all physician-reported): coun-
try, age, sex, ethnicity, smoking status, body mass index, 
physician comanagement of patients, rapid decliners, and 
Deyo–Charlson comorbidity index (CCI).19 Additionally, 
patient-reported variables, general non validated questions 
in the survey, were included as covariates: presence in past 
4 weeks of phlegm, general chest tightness, cough, tired-
ness through lack of sleep, lack of energy, compromised 
daily activities, getting up and ready for the day, ability 
to lead a normal life due to COPD, and the Jenkins Sleep 
Questionnaire score.20 Variables with two-sided P,0.05 
were retained in final regression models.
Regressions were repeated for the following cut 
points: CAT cut point as recommended by the GOLD group, 
optimal CAT cut points recommended by the ROC curves 
analysis, and CAT cut points recommended by the kappa 
statistic analysis.
Continuous variables were split into three binary vari-
ables according to tertiles where possible (or four variables 
in the case of body mass index). This allowed for nonlinear 
effects and to make interpretation easier for clinicians. 
Therefore, all variables used in regression analysis were 
discrete variables.
Statistical analyses were performed using STATA version 
12.1 (StataCorp, College Station, TX, USA).21
Results
general patient population
Primary care physicians (318) and pulmonologists (319) 
from Europe and the US included a total of 3,830 patients, 
with each physician completing a patient record form for 
each patient. Of these patients, 2,054 completed a voluntary 
patient self-completion questionnaire and from this group, 
1,659 were COPD-only and had completed both mMRC 
and CAT and were therefore included in the analysis. 
Patients were recruited in France (254, 15.3%), Germany 
(454, 27.3%), Italy (209, 12.6%), Spain (302, 18.2%), UK 
(52, 3.13%), and the US (388, 23.39%). Patient characteris-
tics are summarized in Table 1.
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Table 1 Physician-reported patient characteristics (n=1,659 unless 
otherwise stated)
Patient characteristics Category n (%) or 
mean (SD)
sex M 
F
1,122 (67.63) 
537 (32.37)
age in years 65.14 (10.44)
ethnicity 
(1,644 patients)
White/Caucasian 1,517 (91.4)
BMI  
(1,594 patients)
kg ⋅ m–2 26.77 (4.93)
smoking status Current smokers 
ex-smokers
533 (32.13) 
1,126 (67.87)
lung function (FeV1) 
(1,073 patients)
FeV1 , 30 
FeV1 $ 30, FeV1 , 50 
FeV1 $ 50, FeV1 , 80 
FeV1 $ 80
45 (4.19) 
203 (18.92) 
713 (66.45) 
112 (10.44)
COPD comanaged (more than  
one doctor), (1,645 patients)
685 (41.29)
how quickly disease is progressing 
(1,631 patients)
slowly/average 
rapid
1,542 (92.95) 
89 (5.36)
Deyo–Charlson  
comorbidity index (CCI)a 
(1,528 patients)
1.40 (0.74)
Notes: aComorbid conditions as described by Deyo–Charlston index19 are mapped 
from as many as ten reported ICD-9-CM secondary diagnosis codes. a single 
summary cumulative value is represented. a score of 0 represents no comorbidities. 
since COPD was a prerequisite in this research, minimum score was 1. Out of 
the 17 conditions, this research could accommodate 12: myocardial infarction, 
congestive heart failure, peripheral vascular disease, dementia, diabetes mellitus, 
cerebrovascular disease, COPD, connective tissue disease, mild liver disease, any 
malignancy including lymphoma and leukemia, aIDs, metastatic solid tumor.
Abbreviations: AIDS, acquired immunodeficiency syndrome; BMI, body mass index; 
COPD, chronic obstructive pulmonary disease; F, female; FeV1, forced expiratory 
volume in 1 second; ICD-9-CM, international classification of disease, ninth revision, 
clinical modification; M, male; SD, standard deviation.
Patient-reported COPD symptoms
Patient-reported general symptoms present in the previous 
4 weeks included tightness in the chest, cough and cough-
ing up of mucus, effect of their COPD on daily activities 
on a scale of 1–10 (no effect to prevented daily activities), 
whether they were restricted in their normal life because of 
COPD on a scale of 1–5 (not restricted at all to completely 
restricted), whether they ever lacked energy, and whether they 
ever experienced tiredness through lack of sleep. Patients also 
reported on the impact of COPD on getting up and ready for 
the day. A complete breakdown of patient-reported COPD 
characteristics can be seen in Table 2.
rOC curves and  
kappa statistic analysis
Table 3 provides the results of the ROC and kappa statistic 
analyses. For each cut point of the CAT score, the sensitivity, 
specificity, Youden index, and the kappa statistic are pre-
sented. The Youden index is maximized at $24 and the kappa 
statistic is maximized at $26.
The AUC of 0.82 (with 95% confidence interval [CI] 
0.80–0.84) in Figure 1 is significantly greater than 0.5 
(P,0.001), which indicates that the CAT score has good 
discriminating power for the GOLD-recommended mMRC 
cut point of $2.
Of note, for an mMRC cut point of $1, the Youden 
index is maximized at the CAT cut point of $19 (0.52, 95% 
CI 0.47–0.56), with an AUC of 0.83 (95% CI 0.81–0.85), 
P,0.001. The kappa measure of agreement is maximized at 
the CAT cut point of $17 (0.47, 95% CI 0.42–0.51).
GOLD groups and definition of movers
gOlD-recommended cut point
Out of the total 1,659 patients, there were 890 (53.65%) 
movers under the GOLD-recommended cut points (GOLD-
recommended mMRC cut point $2 versus the GOLD-
 recommended CAT cut point of $10), three (0.34%) patients 
moved left, from mMRC higher symptomatic GOLD 
groups B and D to the lower CAT-defined symptomatic 
GOLD groups of A and C. Conversely, 887 (99.66%) patients 
moved right from mMRC lower symptomatic GOLD groups 
A and C to the higher CAT-defined symptomatic GOLD 
groups of B and D (see Figure 2).
rOC-recommended cut point
Of the total number of patients who moved under the ROC-
recommended cut point of $24 (429), 170 (39.63%) moved 
left from mMRC higher symptomatic groups B and D to the 
newly defined CAT A and C lower symptomatic groups. The 
majority of patients, 259 (60.37%), still moved to the right 
from mMRC lower symptomatic groups A and C to the higher 
symptomatic ROC CAT-defined groups B and D, albeit to a 
lesser degree (see Figure 3).
Kappa statistic-recommended cut point
Of the total number of patients who moved under the kappa 
statistic-recommended cut point of $26 (403), 230 (57.07%) 
patients moved left from mMRC higher symptomatic groups 
B and D to the newly defined CAT lower symptomatic groups 
A and C. Fewer patients 173 (42.92%) moved to the right 
from mMRC lower symptomatic groups A and C to the higher 
symptomatic groups of B and D defined by kappa statistic 
(see Figure 3).
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Table 2 Patient-reported patient COPD characteristics (n=1,659 unless otherwise stated)
Questions Description n (%) or mean (SD)
Breathing symptoms present in last 4 weeks,  
(1,514 patients)
Coughing up mucus and phlegm 
general tightness in chest 
Cough
649 (39.12) 
340 (20.49) 
878 (52.92)
Breathing condition’s effect on daily activities  
in past week: (1,631 patients)
0 no effect on daily activities 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 Condition prevented daily 
activities
127 (7.66) 
194 (11.69) 
232 (13.98) 
262 (15.79) 
185 (11.15) 
130 (7.84) 
151 (9.10) 
124 (7.47) 
134 (8.08) 
55 (3.32) 
37 (2.23)
extent breathing condition has restricted  
normal life: (1,625 patients)
1 not at all restricted 
2 
3 
4 
5 Completely restricted
226 (13.62) 
460 (27.73) 
482 (29.05) 
353 (21.28) 
104 (6.27)
Do you ever experience the following  
feelings, (1,623 patients)
Constant lack of energy 
Tiredness through lack of sleep
588 (35.44) 
476 (28.69)
Impact breathing condition has on getting up and  
ready for the day: (1,634 patients)
1 no impact 
2 
3 
4 
5 
6 
7 Constant impact
413 (24.89) 
412 (24.83) 
268 (16.15) 
201 (12.12) 
167 (10.07) 
103 (6.21) 
70 (4.22)
Jenkins sleep scale  
(1,588 patients)
(scale 0–20, where 0= no  
problems with sleep and 20= high impact on sleep),
5.12 (4.65)
Abbreviations: COPD, chronic obstructive pulmonary disease; sD, standard deviation.
regression analysis on movers
gOlD-recommended cut point
The following were significantly associated with being a 
mover when defined according to the GOLD-recommended 
CAT cut point: being less than 70 years of age (P,0.001), 
being a smoker (P=0.042), having a cough in the previous 
4 weeks (P=0.011), COPD having a medium effect (3–5 
on a scale of 0–10, where 0 is no effect and 10 prevented 
from undertaking daily activities) on daily activities in 
the previous week (P,0.001), COPD having low restric-
tion (1–3 on a scale of 1–5, where 1 is no restriction and 
5 is complete restriction) on living a completely normal 
life (P,0.001), not experiencing constant lack of energy 
(P=0.001), COPD having no to medium impact (1–4 on 
a scale of 1–7, where 1 is no impact and 7 is constant 
impact) on getting up and ready for the day (P,0.001), 
and an increased Jenkins sleep scale score ($3 on a scale 
of 0–20, where 0 is no impact with sleep and 20 is high 
impact on sleep; P=0.001).
Cut point recommended by rOC analysis
The following were significantly associated with being a mover 
when defined according to the ROC-recommended CAT cut 
point: the presence of a cough in the last 4 weeks (P=0.040), 
COPD having restricted or completely restricted impact (3–5 
on a scale of 1–5) on living a normal life (P,0.001), COPD 
having no to medium impact (1–4 on a scale of 1–7) on getting 
up and ready for the day (P=0.003), and increased Jenkins 
sleep scale score ($3 on a scale of 0–20; P,0.001).
Cut point recommended by the kappa statistic
The following were significantly associated with being a 
mover when defined according to the kappa-recommended 
CAT cut point: being 55 or more years of age (P=0.017), 
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Table 3 rOC curves analysis and kappa statistic analysis
Cut point ROC Points Kappa statistic 
(95% CI)Sensitivity (%) Specificity (%) Youden index  
(bootstrap 95% CI)
$0 100.00 0.00
$1 100.00 0.65 0.01 (0.00–0.01) 0.00 (0.00–0.01)
$2 100.00 1.47 0.01 (0.01–0.02) 0.01 (0.01–0.02)
$3 100.00 2.40 0.02 (0.01–0.03) 0.02 (0.01–0.02)
$4 100.00 3.96 0.04 (0.03–0.05) 0.03 (0.02–0.04)
$5 100.00 5.53 0.06 (0.04–0.07) 0.04 (0.03–0.05)
$6 100.00 7.00 0.07 (0.06–0.08) 0.05 (0.04–0.06)
$7 99.83 9.12 0.09 (0.07–0.11) 0.06 (0.05–0.07)
$8 99.83 10.97 0.11 (0.09–0.13) 0.08 (0.06–0.09)
$9 99.83 15.21 0.15 (0.13–0.17) 0.11 (0.09–0.13)
$10 99.48 18.25 0.18 (0.15–0.20) 0.13 (0.11–0.15)
$11 98.95 22.95 0.22 (0.19–0.24) 0.16 (0.14–0.19)
$12 98.61 27.93 0.27 (0.24–0.29) 0.20 (0.18–0.23)
$13 97.91 32.26 0.30 (0.27–0.33) 0.23 (0.21–0.26)
$14 96.86 35.67 0.33 (0.30–0.36) 0.25 (0.22–0.29)
$15 95.99 39.54 0.36 (0.32–0.38) 0.28 (0.25–0.31)
$16 94.60 42.49 0.37 (0.34–0.41) 0.30 (0.27–0.33)
$17 93.38 47.28 0.41 (0.37–0.44) 0.33 (0.30–0.39)
$18 90.07 50.14 0.40 (0.36–0.44) 0.34 (0.30–0.37)
$19 88.15 54.84 0.43 (0.39–0.47) 0.37 (0.33–0.40)
$20 86.06 58.53 0.45 (0.41–0.49) 0.39 (0.35–0.43)
$21 81.71 62.49 0.44 (0.40–0.48) 0.39 (0.35–0.43)
$22 78.40 67.56 0.46 (0.42–0.50) 0.42 (0.38–0.46)
$23 73.34 71.61 0.45 (0.40–0.50) 0.42 (0.42–0.38)
$24 70.38 76.13 0.47 (0.42–0.51) 0.45 (0.40–0.49)
$25 64.46 80.00 0.44 (0.40–0.49) 0.44 (0.40–0.49)
$26 59.93 84.06 0.44 (0.40–0.49) 0.45 (0.40–0.50)
$27 53.48 87.83 0.41 (0.36–0.46) 0.44 (0.40–0.48)
$28 46.86 91.34 0.38 (0.34–0.42) 0.42 (0.37–0.46)
$29 39.20 94.01 0.33 (0.29–0.38) 0.38 (0.33–0.42)
$30 33.97 96.13 0.30 (0.26–0.34) 0.35 (0.30–0.39)
$31 29.27 97.70 0.27 (0.23–0.30) 0.32 (0.28–0.36)
$32 25.09 98.43 0.24 (0.20–0.27) 0.28 (0.24–0.32)
$33 19.34 99.26 0.19 (0.15–0.22) 0.23 (0.19–0.27)
$34 15.51 99.63 0.15 (0.12–0.18) 0.19 (0.15–0.22)
$35 11.32 99.83 0.11 (0.09–0.14) 0.14 (0.11–0.17)
$36 7.49 99.83 0.07 (0.05–0.09) 0.09 (0.07–0.12)
$37 5.57 99.83 0.05 (0.03–0.07) 0.07 (0.05–0.09)
$38 3.83 99.91 0.04 (0.02–0.05) 0.05 (0.02–0.07)
$39 2.79 99.91 0.02 (0.01–0.04) 0.03 (0.02–0.05)
$40 1.39 99.91 0.01 (0.00–0.02) 0.02 (0.00–0.03)
$41 0.00 100.00
Notes: rOC: 1,659 patients; area under the curve (standard error) =0.82 (0.01); 95% CI 0.80, 0.84. Bold font indicates where the Youden index and kappa statistic are maximized.
Abbreviations: CI, confidence interval; ROC, receiver operating characteristic.
COPD having restricted or complete impact (3–5 on a scale 
of 1–5) on living a completely normal life (P,0.001), COPD 
having a medium impact (3–4 on a scale of 1–7) on getting 
up and ready for the day (P,0.001), and increased Jenkins 
sleep scale score ($3 on a scale of 0–20; P=0.003). Results 
from the three regression analyses are shown in Table 4.
regression analysis on moving left (from 
B/D to a/C) or right (from a/C to B/D)
There were insufficient patients moving left (n=3) for the 
GOLD-recommended cut points to run the regression. 
However, analysis of the ROC-recommended cut points 
showed the following were significantly associated with 
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moving to the right: not being from France (P=0.014), 
being less than 55 years of age (P=0.005), the presence of a 
cough in the last 4 weeks (P=0.003), COPD having little or 
no impact (1–2 on a scale of 1–7) on getting up and ready 
for the day (P=0.032), and an increased Jenkins sleep scale 
score ($7 on a scale of 0–20; P=0.001).
Analysis of the kappa statistic-recommended cut points 
showed the following were significantly associated with mov-
ing to the right: not being from France (P=0.047), being less 
than 55 years of age (P=0.002), being a smoker (P=0.018), 
the presence of a cough in the last 4 weeks (P=0.001), COPD 
having little or no impact (1–2 on a scale of 1–7) on getting 
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Figure 1 graphical representation of the rOC curves analysis for CaT and mMrC.
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Table 4 regression analysis on movers
Odds ratio 95% CI P-value
gOlD-recommended cut points
 age ,70 years 1.62 1.25–2.10 ,0.001
 smoker 1.31 1.01–1.70 0.042
 Cough in last 4 weeks 1.47 1.08–1.98 0.013
 Condition having medium (3–5 on scale 0–10)a effect on daily activities in past week 1.79 1.34–2.40 ,0.001
 Condition having low restriction (1–3 on scale 1–5)b on living a normal life 2.76 1.86–4.09 ,0.001
 not experiencing constant lack of energy 1.77 1.30–2.42 ,0.001
 Condition having no/low impact (1–2 on scale 1–7)c on getting up and ready for the day 2.84 1.75–4.60 ,0.001
 Condition having medium impact (3–4 on scale 1–7)c on getting up and ready for the day 1.85 1.17–2.93 0.009
 Increased Jenkins sleep scale score ($3 on a scale of 0–20)d 1.78 1.28–2.47 0.001
rOC-recommended cut points
 Presence of cough in last 4 weeks 1.34 1.01–1.76 0.040
 Condition having medium restriction (3 on a scale 1–5)b on living a normal life 4.15 2.79–6.17 ,0.001
 Condition having high restriction (4–5 on a scale 1–5)b on living a normal life 2.23 1.36–3.67 0.001
 Condition having no/low/medium impact (1–4 on scale 1–7)c on getting up and ready for the day 1.96 1.27–3.04 0.003
 Increased Jenkins sleep scale score ($3 on a scale of 0–20)d 2.06 1.45–2.91 ,0.001
Kappa statistic-recommended cut points
 age $55 years 1.56 1.08–2.24 0.017
 Condition having medium/high restriction (3–5 on a scale 1–5)b on living a normal life 3.27 2.19–4.89 ,0.001
 Condition having medium impact (3–4 on scale 1–7)c on getting up and ready for the day 1.66 1.21–2.28 0.002
 Condition having high impact (5–7 on scale 1–7)c on getting up and ready for the day 0.64 0.41–0.99 0.047
 Increased Jenkins sleep scale score ($3 on a scale of 0–20)d 1.72 1.20–2.47 0.003
Notes: aWhere 0= no effect and 10= prevented from undertaking daily activities; bwhere 1= no restriction and 5= complete restriction on normal living; cwhere 1= no impact 
and 7= constant impact on getting up and ready for the day; dwhere 0= no impact on sleep and 20= high impact on sleep.
Abbreviations: CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ROC, receiver operating characteristic.
up and ready for the day (P=0.007), and an increased Jenkins 
sleep scale score ($7 on a scale of 0–20) (P=0.001). Detailed 
results are presented in Table 5.
Discussion
Our data would suggest that relying on one marker of COPD 
symptoms may potentially result in under treatment for many 
patients if based on mMRC. Indeed, GOLD recommends 
further symptom assessment in conjunction with mMRC 
administration. However, alignment of the two measures 
by moving the cut point will only be partially successful in 
better categorizing and stabilizing patients to their respec-
tive groups. There will likely still be some movers, though 
greatly reduced as we have shown, and it is these patients 
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who will need additional and possibly more personalized 
treatment.
When modifying the cut point from the GOLD-
 recommended values (mMRC $2; CAT $10) to those which 
identified best alignment using the kappa statistic cut point 
(mMRC $2; CAT $26), the number of movers declines from 
890 to 403. These movers are significantly associated with 
being older, with their COPD condition restricting or com-
pletely restricting their lives, with COPD having a medium or 
high impact on their ability to get up and ready for the day, and 
with an increased Jenkins sleep scale score. These remaining 
movers may represent patients who are more difficult to treat 
and who may require additional follow-up.
It is worth noting that movers from B/D to A/C are also 
significantly likely to be from France. However, as this is a 
borderline significance, it should be viewed with caution, as 
geographic regions should not affect COPD characteristics.
The results of our research concur broadly with a number of 
studies published in the last 2 years since GOLD 2011, which 
have shown that the heterogeneity of COPD does not easily 
translate to “grouping”; that the presence of comorbidities 
complicates diagnosis;22 and that group C, with less symptoms, 
does not necessarily translate into better outcomes.23 Since 
the GOLD strategy 2011, four large retrospective analyses of 
COPD cohorts24–27 have examined the relationships among the 
four GOLD groups. These have been synthesized by Agusti 
et al, finding that the prevalence of patients in each group may 
depend on the population studies and whether they are treated 
through a primary or secondary health setting.24
Further research on misalignment has been produced 
in analyses by Jones et al,29,30 which indicate as our current 
research does, that the two cut points for mMRC and CAT 
are not equivalent. Jones et al29 suggested that an mMRC 
score of $1 is approximately equal to a CAT score of $10 
when diagnosing low symptom patients. Having examined 
the current GOLD cut points and noted, in Jones’ more lim-
ited analysis, the suggested mMRC/CAT score equivalent 
of $1/$10, we chose to use as our starting point the baseline 
of mMRC cut point $2 since this is the midpoint between 
low and high symptoms. CAT offers more granularity and 
breadth of potential cut points to align against mMRC at $2 
and thus, harmonizing the tools via this approach makes for a 
potentially more accurate “fine-tuning” of the cut points.
A study published in 2009 by Lacoma et al31 concluded 
that the influence of a number of factors, such as disease 
severity, comorbidities, and treatment, was more important 
in COPD management, with individual monitoring, than 
establishing cut points for the COPD population as a whole.31 
While we acknowledge this point, we believe that our research 
offers the potential for more accurate grouping, while also 
advocating more personalized management for those who 
move groups and are likely more disease impacted patients 
than nonmovers. Moreover, our research suggests that with 
better aligned cut points, those in need of such individualized 
support will be a smaller number than those who currently 
move groups with the GOLD recommended cut points.
It may be questioned whether such studies present the 
clinician with more questions than answers. However, COPD 
is a global disease, and as an editorial by Franssen and Han32 
reminds us, GOLD is a global strategy, and a simple, more 
uniform approach to COPD disease assessment, management, 
and treatment is key. Any COPD classification must therefore 
Table 5 regression analysis on moving left or righta
Odds ratio 95% CI P-value
rOC-recommended cut points
 not from France 2.45 1.20–5.02 0.014
 age ,55 years 4.07 1.51–10.96 0.005
 Presence of cough in last 4 weeks 2.11 1.29–3.43 0.003
  Condition having little or no impact (1–2 on scale 1–7)b  
On getting up and ready for the day
1.82 1.05–3.16 0.032
 Increased Jenkins sleep scale score ($7 on a scale 0–20)c 2.53 1.47–4.37 0.001
Kappa statistic-recommended cut points
 not from France 2.12 1.01–4.46 0.047
 age ,55 years 3.78 1.62–8.80 0.002
 smoker 1.82 1.11–2.99 0.018
 Presence of cough in last 4 weeks 2.38 1.41–4.02 0.001
  Condition having little or no impact (1–2 on scale 1–7)b  
On getting up and ready for the day
2.18 1.24–3.84 0.007
 Increased Jenkins sleep scale score ($7 on a scale 0–20)c 2.38 1.41–4.02 0.001
Notes: aThere were insufficient patients moving left to run this regression for GOLD-recommended cut points; bwhere 1= no impact and 7= constant impact on getting 
up and ready for the day; cwhere 0= no impact on sleep and 20= high impact on sleep.
Abbreviations: CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ROC, receiver operating characteristic.
International Journal of COPD 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
560
Price et al
be easy to use but also provide sufficient information on the 
disease. Would a more precise alignment of mMRC and CAT 
therefore provide greater accuracy of grouping?
Ultimately, mMRC is a less sensitive tool than CAT 
for classifying COPD patients. It provides a baseline mea-
surement of a patient’s COPD status through measuring 
breathlessness. Indeed, GOLD recommends use of a second 
measure of symptoms, such as CAT, in addition to mMRC 
for comprehensive symptom assessment.3 CAT addresses a 
broader scope of COPD factors, is sensitive to change and 
consequently management of exacerbations,8 and is thus 
well placed as an ongoing assessment tool. Our analysis 
shows that the two tools misclassify a substantial number of 
patients; a combination of the two, particularly if realigned, 
could therefore potentially provide more stable and uniform 
management and treatment of COPD patients.
Data collection through the DSP has some limitations. 
The collected sample is not truly random as it uses the next six 
eligible patients who consult the physician. It may, therefore, 
not represent the overall COPD population as it would capture 
those patients who may be more symptomatic or consult their 
doctors more frequently. Patient selection bias is therefore 
possible. Additionally, only data from those patients who 
chose to complete the voluntary patient self-completion form 
were used in this analysis. There could be potential differ-
ences between those patients who chose to complete the form 
and those who do not, possibly introducing additional bias. 
The quality of data collected depended on accurate reporting 
of information by both physicians and patients. However, 
as data for these analyses were collected at the time of the 
consultation and relate only to that consultation, recall bias 
is unlikely to be an issue. Finally, while minimal inclusion 
criteria governed the selection of participating physicians, 
inclusion will have been influenced by willingness to take 
part and practical considerations of location.
Despite these limitations, our research provides valuable 
real-world physician and patient matched data. The misalign-
ment shown and statistical evidence for a possible change of cut 
points, to measure disease severity, would indicate that further 
research is necessary to understand, characterize, and differenti-
ate the GOLD classification through mMRC and CAT.
Conclusion
Use of mMRC or CAT leads to inconsistencies for COPD 
assessment classification. The optimal clinical management 
of COPD patients, and a closer and more personalized 
approach to the treatment of movers in particular, may require 
alignment of assessment tool cut points, coadministration of 
these tools, and consideration of whether a higher cut point 
for CAT is appropriate. Our research may suggest an oppor-
tunity to investigate a combined score approach to patient 
management based on the worst result of mMRC and CAT. 
Subsequently, the reduced number of remaining movers may 
then identify patients who have greater impact of disease and 
may require a more personalized treatment plan.
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